{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["D'Antoni ML"],"funding":["National Institute of Neurological Disorders and Stroke","NIMH NIH HHS","NIMHD NIH HHS","National Institute of Mental Health","NINDS NIH HHS","National Institute on Minority Health and Health Disparities","NIGMS NIH HHS"],"pagination":["1453-1463"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6151077"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["218(9)"],"pubmed_abstract":["<h4>Background</h4>Myeloid activation contributes to cognitive impairment in chronic human immunodeficiency virus (HIV) infection. We explored whether combination antiretroviral therapy (cART) initiation during acute HIV infection impacts CD163 shedding, a myeloid activation marker, and in turn, implications on the central nervous system (CNS).<h4>Methods</h4>We measured soluble CD163 (sCD163) levels in plasma and cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay in Thais who initiated cART during acute HIV infection (Fiebig stages I-IV). Examination of CNS involvement included neuropsychological testing and analysis of brain metabolites by magnetic resonance spectroscopy. Chronic HIV-infected or uninfected Thais served as controls.<h4>Results</h4>We examined 51 adults with ac"],"journal":["The Journal of infectious diseases"],"pubmed_title":["Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities."],"pmcid":["PMC6151077"],"funding_grant_id":["1R01NS084911","R01 NS084911","R01 NS061696","P20GM103466","U54 MD007584","R01 MH095613","R01MH104141","U54 MD007601","U54MD007584","P20 GM103466","U54MD007601","R01NS061696","R01 MH104141","G12MD007601"],"pubmed_authors":["Rattanamanee S","Milazzo M","Sailasuta N","Sutthichom D","Sithinamsuwan P","Chalermchai T","Luekasemsuk T","Phuang-Ngern Y","Michael N","Eamyoung P","Butterworth O","Tantibul N","Tovanabutra S","D'Antoni ML","Ndhlovu LC","Saetun P","Trautmann L","Crowell T","Ann Eller L","Chan P","Ouellette M","Khadka VS","Slike BM","RV254/SEARCH010, SEARCH011, and RV304/SEARCH013 Study Groups","Nuntapinit B","Chomchey N","Ananworanich J","Karnsomlap P","Sacdalan C","Shiramizu B","O'Connell RJ","Ubolyam S","Trichavaroj R","Byron MM","Puttamaswin S","Kroon E","Pinyakorn S","Turk E","Benjapornpong K","Fletcher JLK","Sukhumvittaya S","Kallianpur KJ","Jongrakthaitae S","Sajjaweerawan C","Savadsuk H","Prueksakaew P","Bandar IS","Tipsuk S","Tragonlugsana N","Akapirat S","Ratnaratorn N","Shikuma C","Spudich S","Valcour V","Intasan J","Krebs SJ","Robb M","Teeratakulpisarn N"],"additional_accession":[]},"is_claimable":false,"name":"Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities.","description":"<h4>Background</h4>Myeloid activation contributes to cognitive impairment in chronic human immunodeficiency virus (HIV) infection. We explored whether combination antiretroviral therapy (cART) initiation during acute HIV infection impacts CD163 shedding, a myeloid activation marker, and in turn, implications on the central nervous system (CNS).<h4>Methods</h4>We measured soluble CD163 (sCD163) levels in plasma and cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay in Thais who initiated cART during acute HIV infection (Fiebig stages I-IV). Examination of CNS involvement included neuropsychological testing and analysis of brain metabolites by magnetic resonance spectroscopy. Chronic HIV-infected or uninfected Thais served as controls.<h4>Results</h4>We examined 51 adults with ac","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2026-05-02T15:54:50.65Z","creation":"2026-04-07T18:13:39.709Z"},"accession":"S-EPMC6151077","cross_references":{"pubmed":["29868826"],"doi":["10.1093/infdis/jiy337"]}}